When: 1st May 2019
Time: 19.30 - 20.30 UK GMT
Recording: Please register to receive the recording
- Learn background information on the burden of chronic liver disease and on gut microbiome composition
- Understand the alterations in the gut-liver axis in chronic liver diseases
- Discover methods to alter the gut-liver axis
- Learn about safety and efficacy of probiotics in chronic liver disease
Liver cirrhosis is an increasingly common disease with high rates of complications, leading to high burden of disease for patients, their relatives and the health care system. Liver cirrhosis is associated with changes in the structure and function of the microbiome (dysbiosis) at several body sites and increased gut permeability, resulting in the translocation of bacterial products into the circulation. This leads to inflammation and as a result of ongoing inflammation to immune dysfunction. Therefore, strategies to revert dysbiosis in liver cirrhosis are promising new approaches to improve health in cirrhosis.
Package Offer: 40% off RRP Bio.Me Barrier + WebinarFor a limited time, we are offering 40% off RRP on Bio.Me Barrier to those who register for Dr Vanessa-Stadlbauer-Köllner's webinar.
Offer price: £29.70
P&P: £2.50 (UK)
1. Buy Bio.Me Barrier by clicking below and filling in the e-form
2. Upon invoice payment, you will be registered and sent the link to the webinar
3. Your discounted Bio.Me Barrier will be shipped out to you.
Dr Vanessa Stadlbauer-Köllner
Dr Vanessa Stadlbauer-Köllner studied Medicine at Karl-Franzens-University in Graz, Austria. After her medical and scientific training in Graz and during a research stay at University College London, UK, she developed her own research group "Transplantation Research“. She is now a hepatology and transplantation consultant at the University Hospital in Graz and an associated professor at the Medical University of Graz. Her main research interests are complications of chronic liver diseases, where she studies the role of the gut microbiome and gut barrier dysfunction in disease development and also as a therapeutic target.